4 completed, 3 terminated, 3 unknown. 3 Phase 3, 3 Phase 4, 1 Not applicable, 1 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 3 | 3 | Completed 2, Terminated 1 |
| Phase 4 | 3 | Terminated 2, Unknown 1 |
| Not applicable | 1 | Unknown 1 |
| Phase 2 | 1 | Completed 1 |
Follow Protease Inhibitors: new trials by email Literature Review of Protease Inhibitors trials Research Report on Protease Inhibitors
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| The American Society of Hematology (ASH) Research Registry: A Multicenter Research Registry of Patients With Hematologic Disease Protease Inhibitors - Benign and Malignant Hematologic Diseases | Unknown | American Society of Hematology | 20000 | 2018-05-10 | 2018-05-24 | |
| Management of Participants With Low-level Persistent Viremia (ANRS 161 L-VIR) Protease inhibitor, Isentress® (raltegravir), Counseling arm - HIV-1 Infection, Treatment Resistant Disorders | Phase 3 | Terminated | ANRS, Emerging Infectious Diseases | 4 | 2014-12-01 | 2015-10-12 |
| Multicentre Study To Assess Changes In Bone Mineral Density Of The Switch From Protease Inhibitors To Dolutegravir In HIV-1-Infected Subjects With Low Bone Mineral Density Dolutegravir, 50mg every 24 hours, Protease Inhibitor/ritonavir - HIV-1 Infection | Phase 3 | Completed | Fundación FLS de Lucha Contra el Sida, las Enfermedades Infecciosas y la Promoción de la Salud y la Ciencia | 75 | 2014-01-01 | 2015-11-30 |
| MARCH Central Nervous System Substudy Arm 1 TNucleotide Analogue Reverse Transcriptase Inhibitors and Boosted Protease Inhibitors, Arm 2 Maraviroc and Protease Inhibitors, Arm 3 Maraviroc and Nucleotide Analogue Reverse Transcriptase Inhibitors - HIV-1 Infection | Completed | Kirby Institute | 28 | 2012-06-01 | 2016-01-20 | |
| Triple-Therapy in Patients With HCV Genotype 3 Who Previously Failed Treatment Boceprevir - Hepatitis C | Phase 3 | Completed | University of Calgary | 11 | 2012-05-01 | 2015-09-21 |
| Influence of Nevirapine on HCV Viral Load Nevirapine, efavirenz, protease inhibitors - HCV Infection., HCV Viral Load. | Not applicable | Unknown | Valme University Hospital | 60 | 2011-01-01 | 2011-01-17 |
| Protease Inhibitor Monotherapy Versus Ongoing Triple-therapy in the Long Term Management of HIV Infection (PIVOT) Protease Inhibitor, Standard-of-care Antiretroviral therapy - HIV Infection, Acquired Immunodeficiency Syndrome | Phase 4 | Unknown | Medical Research Council | 587 | 2008-11-01 | 2012-10-10 |
| A Study With TMC125 in Human Immunodeficiency Virus (HIV) Type 1 Infected Patients, Who Were Treated With TMC125 Arm in a Sponsor-Selected TMC125 Study Etravirine (ETR), Nucleotide reverse transcriptase inhibitors (NRTIs), Protease inhibitors (PIs) - Human Immunodeficiency Virus Type 1 | Phase 2 | Completed | Tibotec Pharmaceuticals, Ireland | 211 | 2005-06-01 | 2013-06-20 |
| Evaluation of the Occurrence of Lipoatrophy in HIV-1 Infected Naive Patients non-nucleoside reverse transcriptase inhibitors, nucleoside reverse transcriptase inhibitors, protease inhibitor - HIV Infections, HIV-Associated Lipodystrophy Syndrome | Phase 4 | Terminated | French National Agency for Research on AIDS and Viral Hepatitis | 112 | 2003-11-01 | 2005-11-15 |
| Study Evaluating the Impact on Fat Distribution of Nucleoside Reverse Transcriptase Inhibitor (NRTI)-Sparing Regimens in Antiretroviral Experienced Patients With Lipoatrophy non-nucleoside reverse transcriptase inhibitors, nucleoside reverse transcriptase inhibitors, protease inhibitors - HIV Infections, HIV Lipodystrophy Syndrome | Phase 4 | Terminated | French National Agency for Research on AIDS and Viral Hepatitis | 100 | 2001-01-01 | 2005-11-15 |
HIV Infections (4) · Acquired Immunodeficiency Syndrome (2) · HIV-Associated Lipodystrophy Syndrome (2) · Hepatitis C (2) · Anemia, Sickle Cell (1) · Immune System Diseases (1) · Multiple Myeloma (1) · Osteoporosis (1) · RNA Virus Infections (1) · Sexually Transmitted Diseases, Viral (1) · Viremia (1) · Virus Diseases (1)
French National Agency for Research on AIDS and Viral Hepatitis (2) · ANRS, Emerging Infectious Diseases (1) · American Society of Hematology (1) · Fundación FLS de Lucha Contra el Sida, las Enfermedades Infecciosas y la Promoción de la Salud y la Ciencia (1) · Kirby Institute (1) · Medical Research Council (1) · Tibotec Pharmaceuticals, Ireland (1) · University of Calgary (1) · Valme University Hospital (1)
France (3) · Spain (2) · Argentina (1) · Canada (1) · Thailand (1) · United Kingdom (1) · United States (1)
Dominique Costagliola (2) · Alan Winston, MD (1) · Alexis Thompson, MD,MPH (1) · Claudine Duvivier, MD (1) · Jade Ghosn, MD, PhD (1) · Marc Antoine Valantin, MD (1) · Nick Paton, MD (1) · Samuel Lee, MD (1)
PMID 18641035, PMID 19363330, PMID 19487903, PMID 23646111
2014 (1)